Partner at Novo Holdings
View Live Interactive Profile →Natalie Sacks is a Partner in Novo Holdings' Venture Investments team, based with Novo Holdings US Inc. Novo Holdings describes her as an oncologist and drug developer with over 20 years of experience in the biotechnology industry. Before joining Venture Investments she was Chief Medical Officer at Harpoon Therapeutics, and earlier held development and executive leadership roles at Onyx Pharmaceuticals, which was acquired by Amgen, as well as Aduro, Exelixis and Cell Genesys. She held a faculty appointment at the University of California, San Francisco for more than ten years as a volunteer assistant clinical professor of medicine in the Division of Hematology/Oncology. She holds a BA in mathematics from Bryn Mawr College, an MS in biostatistics from Harvard University School of Public Health and an MD from the University of Pennsylvania School of Medicine.